HOME >> MEDICINE >> NEWS
Marrow injection gets damaged hearts moving

CHICAGO, Nov. 17 In one of the first studies of its kind, researchers discovered that bone marrow cells injected directly into the heart significantly enhanced function, according to findings reported today at the American Heart Association's Scientific Sessions 2002.

Heart wall contraction improved significantly after patients had their own bone marrow injected into scar tissue caused by heart attacks. Heart wall motion improved within weeks of treatment and persisted for at least 10 months after treatment in 14 patients.

"The benefit (of transplanting bone marrow into scar tissue of the heart) could be seen only six weeks after injection," says Manuel Galinanes, M.D., a heart surgeon at the University of Leicester in the United Kingdom.

The technique is a new way to strengthen heart muscle after a heart attack, he adds.

Bone marrow has been used for years to treat certain types of cancer and disorders affecting the body's disease-fighting immune system. Marrow transplantation is an attractive therapy because it can form healthy new cells. Bone marrow also has the potential to develop into many different types of cells.

"Bone marrow not only can differentiate into heart cells, but also smooth muscle cells, connective tissue cells and other types of cells to reconstitute the entire structure of a tissue," Galinanes says.

The investigators have yet to prove that bone marrow creates a new cellular infrastructure in heart scar tissue, but "that is the only possible explanation," Galinanes says.

The British team treated patients whose hearts had been severely damaged by heart attacks. All patients had low ejection fractions, meaning the heart muscle had lost much of its ability to pump blood into the circulation. The bone marrow injections were given during non-emergency coronary artery bypass surgery. Before surgery, each patient had a stress test to confirm abnormal movement in the walls of the heart muscle. The test invo
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
17-Nov-2002


Page: 1 2 3

Related medicine news :

1. Less Toxic Bone Marrow Transplant Technique May Have More Powerful Anti-Cancer Effect
2. Organ Transplants Helped By Donor Bone Marrow, University Of Pittsburgh Researchers Report At National Transplant Meetings
3. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
4. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
5. Duke Researchers Identify New Pulmonary Syndrome Associated With Bone Marrow Transplantation For Breast Cancer
6. Medically supervised drug injection facilities safer for users
7. Study examines harm reduction among injection drug users
8. Transparent orthodontic brackets by microinjection
9. Pain relief could be easy with a simple injection
10. RFA safe for treating liver tumors pushing on GI tract; Alcohol injection makes RFA more effective
11. Naltrexone injections for alcohol dependence: once-a-month treatment helps maintain sobriety

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Marrow injection gets damaged hearts moving

(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
Cached News: